TARGETING UNMET GLOBAL NEEDS IN MULTI-BILLION DOLLAR MARKETS
review our transforming drug-delivery platforms
Virpax® Pharmaceuticals Inc., (Nasdaq: VRPX) is a specialty pharmaceutical company focused on pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur delivers local anesthetic at the wound/incision site, effectively managing post-operative pain for an extended 96 hours.
With a focus on optimizing non-addictive medications, our drug delivery platforms target unmet global needs in markets such as Post Operative Pain, Severe Pain, Post Cancer Pain, and Rare Pediatric Epilepsy, including orphan diseases like Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome. Virpax is at the forefront of providing differentiated solutions for these diverse healthcare challenges.
Virpax is traded on
View our presentation
OPTIMIZING NON-ADDICTIVE DRUG DELIVERY
IN THE MANAGEMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES
Probudur™ Lead Product Candidate
Injectable liposomal Bupivacaine
Probudur is a next generation liposomal bupivacaine formulation that has demonstrated 96 hours pain control after administering a single injection at the wound site in animal studies.
Envelta is an innovative intranasal enkephalin powder formulation that has demonstrated an ability to control severe pain without exhibiting respiratory depression, drug seeking behavior and drug tolerance in animal studies compared to morphine.
NobrXiol is an innovative pharmaceutical-grade cannabidiol intranasal spray powder being developed to manage Rare Pediatric Epilepsy without being metabolized by the liver; hence, avoiding drug to drug interactions caused by approved oral dosing.